Imaging , Diagnosis , Prognosis Notch 1 Expression , Which Is Related to p 65 Status , Is an Independent Predictor of Prognosis in Colorectal Cancer

Purpose: Notch1 has been proven to be aberrantly expressed in colorectal cancer and related to tumor differentiation status. However, few previous studies concentrated on the predictive role of Notch1 expression on the overall survival of patients with colorectal cancer. This study explored expression of Notch1 and its relationship with p65 and prognosis in colorectal cancer. Experimental Design: Two independent study cohorts were involved in the present study. Clinical specimens from 941 eligible patients were constructed into tissue microarrays. The expression of Notch1 and p65 protein was investigated by immunohistochemistry. Results: Statistically significant positive correlations were found between protein expression of Notch1 and p65 in both retrospective and prospective study cohorts. Patients with higher Notch1 expression showed a trend of having shorter survival time, whereas patients with lower Notch1 expression had better survival in both study cohorts. In multivariate analysis, Notch1 expression was proven to be an independent predictor of prognosis. Moreover, the prognostic value of Notch1 might differ according

[1]  W. Wang,et al.  Notch1 and Notch2 have opposite prognostic effects on patients with colorectal cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[3]  P. Kantoff,et al.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Mariani,et al.  Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  James R. Anderson,et al.  Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Hongwei Zhang,et al.  High Level of Notch1 Protein is Associated with Poor Overall Survival in Colorectal Cancer , 2010, Annals of Surgical Oncology.

[8]  J. Frasor,et al.  Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. , 2009, Cancer research.

[9]  A. Jemal,et al.  Worldwide Variations in Colorectal Cancer , 2009, CA: a cancer journal for clinicians.

[10]  Hongwei Zhang,et al.  Notch2 Expression Is Decreased in Colorectal Cancer and Related to Tumor Differentiation Status , 2009, Annals of Surgical Oncology.

[11]  Y. Lévy,et al.  Notch Increases T/NK Potential of Human Hematopoietic Progenitors and Inhibits B Cell Differentiation at a Pro‐B Stage , 2009, Stem cells.

[12]  Huahong Xie,et al.  Notch1 Expression in Colorectal Carcinoma Determines Tumor Differentiation Status , 2009, Journal of Gastrointestinal Surgery.

[13]  K. Leong,et al.  The Notch pathway in prostate development and cancer. , 2008, Differentiation; research in biological diversity.

[14]  R. Labianca,et al.  Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Park,et al.  Protein Expression Profiling and Molecular Classification of Gastric Cancer by the Tissue Array Method , 2007, Clinical Cancer Research.

[16]  J. Meyerhardt,et al.  Adjuvant Treatment of Colorectal Cancer , 2007, CA: a cancer journal for clinicians.

[17]  A. Efstratiadis,et al.  Notch, Myc and Breast Cancer , 2007, Cell cycle.

[18]  C. Waes.  Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer , 2007 .

[19]  S. Bray.  Notch signalling: a simple pathway becomes complex , 2006, Nature Reviews Molecular Cell Biology.

[20]  G. Lockwood,et al.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. , 2005, Cancer research.

[21]  J. Aster,et al.  Multiple niches for Notch in cancer: context is everything. , 2004, Current opinion in genetics & development.

[22]  Hans Clevers,et al.  Notch1 functions as a tumor suppressor in mouse skin , 2003, Nature Genetics.

[23]  James D. Griffin,et al.  Growth Suppression of Pre-T Acute Lymphoblastic Leukemia Cells by Inhibition of Notch Signaling , 2003, Molecular and Cellular Biology.

[24]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  David L Rimm,et al.  Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. , 2002, Cancer research.

[26]  S. Baylin,et al.  Notch signaling induces cell cycle arrest in small cell lung cancer cells. , 2001, Cancer research.

[27]  Raphael Kopan,et al.  Notch signaling: from the outside in. , 2000, Developmental biology.

[28]  Jon C. Aster,et al.  Essential Roles for Ankyrin Repeat and Transactivation Domains in Induction of T-Cell Leukemia by Notch1 , 2000, Molecular and Cellular Biology.

[29]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.

[30]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[31]  I. Greenwald,et al.  LIN-12/Notch signaling: lessons from worms and flies. , 1998, Genes & development.

[32]  Raphael Kopan,et al.  Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain , 1998, Nature.

[33]  G. Struhl,et al.  Nuclear Access and Action of Notch In Vivo , 1998, Cell.

[34]  A. Bigas,et al.  Notch1 and Notch2 Inhibit Myeloid Differentiation in Response to Different Cytokines , 1998, Molecular and Cellular Biology.

[35]  S. Artavanis-Tsakonas,et al.  Intracellular Cleavage of Notch Leads to a Heterodimeric Receptor on the Plasma Membrane , 1997, Cell.

[36]  G. Aithal,et al.  Concerns about chemotherapy are legitimate , 1996, BMJ.

[37]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[38]  J. Thigpen.  HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients , 2011 .

[39]  Malay Mandal,et al.  Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. , 2007, Nature medicine.

[40]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.

[41]  D L Rimm,et al.  Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  J. Norton,et al.  Linking Notch signaling, chromatin remodeling, and T‐cell leukemogenesis , 2000, Journal of cellular biochemistry. Supplement.